m****g
发帖数: 530 | 1 WOBURN, Mass.--(BUSINESS WIRE)--Mar 31, 2010 - ArQule, Inc. (Nasdaq: ARQL)
today announced that
ARQ 197, when used in combination with erlotinib, demonstrated a 66%
improvement in median
Progression-Free Survival (PFS) in patients with advanced, refractory non-
small cell lung cancer (NSCLC). In
the intent to treat (ITT) population (n = 167), median PFS was 16.1 weeks in
the ARQ 197 plus erlotinib
arm, compared with 9.7 weeks in the erlotinib plus placebo arm.
The difference in PFS between the t |
|
